March 16, 2012 at 08:00 AM EDT
Echo Therapeutics, Inc. Announces 2011 Financial Results

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.  Echo's Annual Report on Form 10-K is available through Echo's website at www.echotx.com.

2011 Corporate Highlights:

  • Echo added key executives to its management team as part of the company's plan to accelerate the development and commercialization of Symphony and other new products contemplated in its growth strategy.
  • Echo's common stock began trading on the Nasdaq Capital Market in June, providing more liquidity to its shareholders and increased visibility to the investment community over the short and long-term.
  • Echo successfully completed two clinical trials of Symphony in patients with and without diabetes that showed that Symphony successfully monitors patient glucose levels and has the potential to be an important tool for the tracking and trending of glucose.  To date, Echo has completed eight positive pilot studies of Symphony with a combined average error rate, often referred to as mean absolute relative difference (MARD), of 12.4%.
  • Echo announced multiple patents and trademark grants throughout the year that will provide its products with long-term market protection.  Echo has obtained 12 U.S. patents and 42 foreign patents, and has 39 patent applications pending in the U.S. and foreign countries.

"We made very tangible progress during 2011 and we achieved some very important milestones. We believe the clinical data from the most recent trials further demonstrates Symphony's significance and potential for the monitoring of glucose levels," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "Additionally, we raised significant capital through a series of private financings and warrant exercises that brought our year-end cash position to nearly $9 million.  With a strengthened and simplified balance sheet, and an experienced management team, Echo is focused on the continued, accelerated pace of product development finalization and clinical validation necessary for regulatory clearance of the Symphony tCGM System in both Europe and the U.S."

Fiscal Year 2011 Financial Results

For fiscal year 2011, the Company was principally involved with the product development and clinical studies of its Symphony tCGM System. Echo reported approximately $447,000 in total revenues during 2011 compared to $428,000 during 2010.  Operating expenses for 2011 of $8.7 million increased by approximately $3.4 million compared to 2010 reflecting our increased investment in product development and corporate structure.  The net loss for 2011 was $16.7 million, or ($0.49) per share, compared to a net loss of $4.3 million, or ($0.15) per share for 2010.  The Company reported a cash balance of approximately $9.0 million as of December 31, 2011.

2012 Development Outlook

"We believe that the significant accomplishments and progress made in 2011 has set the stage for an exciting and productive 2012.  Building on the positive momentum of the previous two Symphony studies, we anticipate positive results from our current critical care study in the near term," Dr. Mooney concluded. "This year we are focused on completing several key milestones that we believe will clear the path toward commercialization of Symphony and will significantly increase shareholder value."

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx


Echo Therapeutics, Inc.

Condensed Consolidated Balance Sheets



December 31,

2011


December 31,

2010

ASSETS




Current Assets:




Cash and cash equivalents

$    8,995,571


$    1,342,044

Other current assets

567,940


621,693

Total current assets

9,563,511


1,963,737

Net property and equipment (including assets under capitalized leases)

317,731


48,034

Other Assets:




Intangible assets, net of accumulated amortization

9,625,000


9,625,000

Restricted cash, deposits and other assets

20,565


275,499

Total other assets

9,645,565


9,900,499

Total assets

$  19,526,807


$  11,912,270





LIABILITIES AND STOCKHOLDERS' EQUITY




Current Liabilities:




Accounts payable

$       365,298


$       605,634

Deferred revenue

123,708


405,454

Derivative warrant liability

1,035,337


1,544,996

Accrued expenses and other liabilities

968,120


565,546

Total current liabilities

2,492,463


3,121,630

Deferred revenue, notes payable and capital lease obligation, net of current portion

65,755


88,356

Total liabilities

2,558,218


3,209,986

Commitments




Stockholders' Equity:




Perpetual redeemable preferred stock, Series B

-


2

Convertible preferred stock, Series C & D

30,160


49

Common stock

385,442


311,264

Additional paid-in capital

98,116,327


79,646,385

Common stock subscribed for but not paid for or issued

6,667


285,000

Accumulated deficit

(81,570,007)


(71,540,416)

Total stockholders' equity

16,968,589


8,702,284

Total liabilities and stockholders' equity

$  19,526,807


$  11,912,270





Condensed Consolidated Statements of Operations



Years Ended December 31,


2011


2010

Licensing revenue

$        302,059


$        225,868

Other revenue

145,152


202,592

Total revenues

447,211


428,460





Operating Expenses:




Research and development

3,796,127


2,578,852

Selling, general and administrative

4,905,757


2,760,062

Total operating expenses

8,701,884


5,338,914

Loss from operations

(8,254,673)


(4,910,454)





Other Income (Expense):




Interest income (expense), net

(9,118)


(36,030)

Gain (loss) on extinguishment of debt/payables

(1,514)


183,863

Gain (loss) on disposal of assets

(1,348)


-

Qualified therapeutic research grant

-


244,480

Derivative warrant liability gain (loss)

(1,762,938)


371,345

Other income (expense), net

(1,774,918)


763,658

Net loss

(10,029,591)


(4,146,796)

Accretion of dividends on Series B Convertible Perpetual
Redeemable Preferred Stock

(157,733)


(131,659)

Deemed dividend on beneficial conversion feature of Series D Convertible Preferred Stock

(1,975,211)


-

Deemed dividend on warrant repricings

(4,559,761)


-

Net loss applicable to common shareholders

$  (16,722,296)


$    (4,278,455)

Net loss per common share, basic and diluted

$             (0.49)


$             (0.15)

Basic and diluted weighted average common shares outstanding

34,174,895


29,031,158




SOURCE Echo Therapeutics, Inc.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here